Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupMalcolm J. Moore, Wendy R. Parulekar, J. Randolph Hecht et al.|Journal of Clinical Oncology|2007Cited by 3.9k
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsAlona Zer, Frances A. Shepherd, Keyue Ding et al.|Journal of Thoracic Oncology|2015Cited by 55